Literature DB >> 29762641

Functional genomics: paving the way for more successful cancer immunotherapy.

Reham Ajina1, Danielle Zamalin1, Louis M Weiner1.   

Abstract

Immunotherapies have revolutionized cancer treatment. Immunotherapy is effective for the treatment of a wide range of cancer types and can mediate complete and durable tumor regression. Nonetheless, the field still faces many significant challenges, such as the need for personalized therapeutic strategies and better biomarkers, the difficulty of selecting the right combination therapy, and resistance to currently available immunotherapies. Both cancer and host immunity comprise significantly diverse and complex ecosystems, making immunogenomics an ideal field for functional genomics analysis. In this review, we describe the cancer-immunity cycle, how cancer cells manage to evade immune attack and the current hurdles in the path of cancer immunotherapy. Then, we discuss how functional genomics approaches can pave the way for more successful cancer immunotherapies.
© The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cancer; checkpoints; functional genomics; immunity; immunotherapy

Mesh:

Year:  2019        PMID: 29762641      PMCID: PMC6430032          DOI: 10.1093/bfgp/ely017

Source DB:  PubMed          Journal:  Brief Funct Genomics        ISSN: 2041-2649            Impact factor:   4.241


  103 in total

1.  Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.

Authors:  Beatriz M Carreno; Vincent Magrini; Michelle Becker-Hapak; Saghar Kaabinejadian; Jasreet Hundal; Allegra A Petti; Amy Ly; Wen-Rong Lie; William H Hildebrand; Elaine R Mardis; Gerald P Linette
Journal:  Science       Date:  2015-04-02       Impact factor: 47.728

Review 2.  The immune network in pancreatic cancer development and progression.

Authors:  S M Wörmann; K N Diakopoulos; M Lesina; H Algül
Journal:  Oncogene       Date:  2013-07-15       Impact factor: 9.867

Review 3.  Migrating into the Tumor: a Roadmap for T Cells.

Authors:  Lieke L van der Woude; Mark A J Gorris; Altuna Halilovic; Carl G Figdor; I Jolanda M de Vries
Journal:  Trends Cancer       Date:  2017-11-06

4.  Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.

Authors:  Xinqi Wu; Anita Giobbie-Hurder; Xiaoyun Liao; Courtney Connelly; Erin M Connolly; Jingjing Li; Michael P Manos; Donald Lawrence; David McDermott; Mariano Severgnini; Jun Zhou; Evisa Gjini; Ana Lako; Mikel Lipschitz; Christine J Pak; Sara Abdelrahman; Scott Rodig; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2016-12-21       Impact factor: 11.151

Review 5.  Towards personalized, tumour-specific, therapeutic vaccines for cancer.

Authors:  Zhuting Hu; Patrick A Ott; Catherine J Wu
Journal:  Nat Rev Immunol       Date:  2017-12-11       Impact factor: 53.106

6.  Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Authors:  Howard L Kaufman; Jeffery Russell; Omid Hamid; Shailender Bhatia; Patrick Terheyden; Sandra P D'Angelo; Kent C Shih; Céleste Lebbé; Gerald P Linette; Michele Milella; Isaac Brownell; Karl D Lewis; Jochen H Lorch; Kevin Chin; Lisa Mahnke; Anja von Heydebreck; Jean-Marie Cuillerot; Paul Nghiem
Journal:  Lancet Oncol       Date:  2016-09-01       Impact factor: 41.316

Review 7.  Immune escape of tumors: apoptosis resistance and tumor counterattack.

Authors:  Frederik H Igney; Peter H Krammer
Journal:  J Leukoc Biol       Date:  2002-06       Impact factor: 4.962

Review 8.  Improved endpoints for cancer immunotherapy trials.

Authors:  Axel Hoos; Alexander M M Eggermont; Sylvia Janetzki; F Stephen Hodi; Ramy Ibrahim; Aparna Anderson; Rachel Humphrey; Brent Blumenstein; Lloyd Old; Jedd Wolchok
Journal:  J Natl Cancer Inst       Date:  2010-09-08       Impact factor: 13.506

Review 9.  The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy.

Authors:  Mateusz Legut; David K Cole; Andrew K Sewell
Journal:  Cell Mol Immunol       Date:  2015-04-13       Impact factor: 11.530

Review 10.  Tumour Cell Heterogeneity.

Authors:  Laura Gay; Ann-Marie Baker; Trevor A Graham
Journal:  F1000Res       Date:  2016-02-29
View more
  3 in total

Review 1.  Banking with precision: transfusion medicine as a potential universal application in clinical genomics.

Authors:  Celina Montemayor; Patricia A R Brunker; Margaret A Keller
Journal:  Curr Opin Hematol       Date:  2019-11       Impact factor: 3.284

Review 2.  Immunotherapy for pediatric brain tumors: past and present.

Authors:  Jessica B Foster; Peter J Madsen; Meenakshi Hegde; Nabil Ahmed; Kristina A Cole; John M Maris; Adam C Resnick; Phillip B Storm; Angela J Waanders
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

Review 3.  T-Cell Immunity in Pancreatic Cancer.

Authors:  Reham Ajina; Louis M Weiner
Journal:  Pancreas       Date:  2020-09       Impact factor: 3.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.